Sachs Associates

"Beyond Incretins: Canary Cure's CCT-217 Dual siRNA Gene Silencing Therapy Offers a Novel Approach to Obesity with Superior Fat Loss, Increase in Lean Muscle and Improved Body Composition: Canary Cure Biotechnologies, a late stage pre-clinical company, is tackling the growing obesity and diabetes crisis with CCT-217, a first-in-class dual siRNA gene precision therapy. Our pioneering approach offers a significant advancement over existing treatments, focusing on precise targeting and durable effects.  Studies show CCT-217's innovative mechanism of action reprograms white fat cells leading to more metabolically active brown fat, leading to a remarkable 25% increase in lean muscle mass while simultaneously reducing fat mass and increasing resting energy expenditure. This not only promotes weight loss but also improves metabolic function and overall health.  What sets CCT-217 apart is its unique ability to preserve lean body mass, a crucial factor often overlooked by current therapies. This proactive approach ensures healthier and more sustainable weight loss, addressing a critical unmet need in the obesity treatment landscape.  Furthermore, CCT-217's potential for twice-annual, self-administered dosing offers unparalleled convenience and patient compliance. This long-acting profile, combined with its targeted action and impressive efficacy, positions CCT-217 as a game-changer in the $200 Billion ( by 2030) Obesity treatment market.  Invest in Canary Cure's therapeutic development and support our mission to revolutionize metabolic disease management with CCT-217, a breakthrough therapy poised to redefine the future of obesity care. Meet Canary Cure Therapeutics @ #Sachs_BOIF More Info @ https://lnkd.in/dyF_BCWq #ObesityInnovation #BioPharma #ObesityTreatment #HealthcareInnovation #BiotechInvestment #LifeSciences #Cardiometabolic #BiotechInObesity #BioPharmaIndustry #BiotechConference #ObesityEpidemic #TherapeuticInnovation #ObesityHealth #InvestmentOpportunity #BioTechInvestment #InnovationInHealth"

Claude Cohen-Bacrie is an entrepreneur in Medtech and founded two innovative companies in the field of ultrasound imaging. He was co-founder of SuperSonic imagine in 2005, and acted as executive vice president, Chief Technology Officer and Chief Operating Officer of the company until end 2017. The company was IPOed in 2014 and has recenty been acquired by Hologic. In 2018, Claude founded E-Scopics, a point of care ultrasound company, which aims at democratizing the role of ultrasound toward all healthcare professionals ultimately. The company owns and develops proprietary technologies to allow dematerialization of ultrasound imaging architectures for innovative devices with strong clinical and technical differentiations within the point of care market. Claude was previously managing ultrasound research between Philips Research and Philips Medical Systems. He is also former board member of Eye Tech Care, which develops High Intensity Focused Ultrasound technology for glaucoma treatment and act as coach for several entrepreneur within M2Care incubator. Claude is a scientist by training, who further specialized in Signal and image processing and a thesis in Medical Imaging. His qualifications also include TRIUM EMBA 2015. Meet Claude COHEN-BACRIE @ #Sachs_BOIF More Info @ https://lnkd.in/dyF_BCWq #ObesityInnovation #BioPharma #ObesityTreatment #HealthcareInnovation #BiotechInvestment #LifeSciences #Cardiometabolic #BiotechInObesity #BioPharmaIndustry #BiotechConference #ObesityEpidemic #TherapeuticInnovation #ObesityHealth #InvestmentOpportunity #BioTechInvestment #InnovationInHealth

Dr. Lombardo is Chief Executive Officer of Noema Pharma AG. She is a seasoned biopharma executive with more than 25 years of experience in the CNS space, spanning clinical practice, academic research, large pharma and biotech. She joined Noema Pharma’s Board of Directors in 2021, and transitioned to CEO in 2023. In 2019, Dr Lombardo co-founded Arvelle Therapeutics where she served as Chief Medical Officer. Dr. Lombardo was instrumental in building Arvelle into a launch-ready European CNS company, which was acquired by Angelini Pharma in 2021. Prior to joining Noema Pharma, Dr. Lombardo was President of the Therapeutics Division at gene therapy company Kriya Therapeutics. She has also held senior roles in clinical and medical development at Pfizer, Forum Pharmaceuticals and Axovant Sciences. She was previously on the faculty of Columbia University College of Physicians and Surgeons. Dr. Lombardo completed two fellowships, one in neuroreceptor imaging and one in molecular genetics. She completed her residency in psychiatry at Columbia University, and obtained her medical degree from Yale University, an M. Phil from the University of Cambridge and a bachelor’s degree from Brown University. Meet Ilise Lombardo @ #Sachs_NIF More Info @ https://lnkd.in/dHgcp4fq #Neuroscience #Neurotech #NeurologyInnovation #BrainHealth #CNSDisorders #NeurologicalDiseases #ADPD #Neuropsychiatry #PsychedelicResearch #NeuroTechInvestment #Biotech #MedicalInnovation #NeuroscienceForum #NeuroInvestment #NextGenMedicine #NeuroscienceResearch #MentalHealthInnovation #BiotechIndustry

Dr. Acosta is a physician, scientist, inventor, and entrepreneur. He is board certified in Internal Medicine, Gastroenterology and Hepatology, and Obesity Medicine and Nutrition. Dr. Acosta holds an MD from Universidad San Francisco De Quito, Ecuador, and a PhD from University of Florida, Gainesville. Currently, he is an Associate Professor of Medicine and Consultant in Gastroenterology and Hepatology at the Mayo Clinic, Rochester, MN. He co-directs the Nutrition Obesity Research Program and directs the Precision Medicine for Obesity Program at Mayo Clinic. Dr. Acosta's goal is to treat and ultimately cure obesity, which he considers this century's health epidemic. Dr. Acosta's research focus on precision medicine for obesity with the aim to identify the right therapy for the right patient, minimizing side effects. His research is supported by the National Institute of Health, many foundations and industry. He is a recognized national and international speaker with many patents, more than 140 peer reviewed publications, including publications in the Lancet, Gut and Gastroenterology, and many book chapters. His works has been featured in the New York Times, Time, CNN, NPR, among others. He won the 40-under-40 innovation award at Minneapolis Business Journal 2020 and Tekne Award (Winners exemplify Technology Innovation in Minnesota). Meet Andres Acosta M.D., Ph.D. @ #Sachs_BOIF More Info @ https://lnkd.in/dyF_BCWq #ObesityInnovation #BioPharma #ObesityTreatment #HealthcareInnovation #BiotechInvestment #LifeSciences #Cardiometabolic #BiotechInObesity #BioPharmaIndustry #BiotechConference #ObesityEpidemic #TherapeuticInnovation #ObesityHealth #InvestmentOpportunity #BioTechInvestment #InnovationInHealth

Cornelia plays a pivotal role as co-managing director in building GOLDTRACK Ventures, a lighthouse life science fund and venture capital platform in Central Germany. She spearheads international strategic initiatives to attract high-impact investments, fosters collaborations with key stakeholders, and drives the development of innovative funding solutions to support groundbreaking advancements in biotechnology and healthcare. She demonstrates expertise in building robust networks within the life sciences ecosystem, and positioning the fund as a leading player in the region. Her professional journey spans over 25 years in investor relations, international venture capital, corporate communications, entrepreneurship and is an active investor in a range of technology and life science sectors. Previously, Cornelia was Head Investor Relations to stock listed JENOPTIK AG, before setting up the German Investment arm of a UK VC fund manager. Cornelia's prior international experience was also leveraged to create value in international portfolio companies in the fund.  With a passion for life science Cornelia currently works with leap:up (former BIOSAXONY), successful life sciences association, based in Saxony, Germany, to grow the investment profile of region, through actively campaigning international for access to capital and building a strong cluster, whilst deploying investor relations advice. Cornelia is also a member of the Sustainable Finance Advisory Board of the Federal Government during the 20th legislative term. This enables her to help bridging the gaps between diverse stakeholders, fostering the development of sustainable finance standards and innovative products. She is also the driving force behind the Saxonian Chapter of the German Female Entrepreneurs Association and initiator of BAM! Business Angel Network of Central Germany. Meet Cornelia Jahnel @ #Sachs_NIF More Info @ https://lnkd.in/dHgcp4fq #Neuroscience #Neurotech #NeurologyInnovation #BrainHealth #CNSDisorders #NeurologicalDiseases #ADPD #Neuropsychiatry #PsychedelicResearch #NeuroTechInvestment #Biotech #MedicalInnovation #NeuroscienceForum #NeuroInvestment #NextGenMedicine #NeuroscienceResearch #MentalHealthInnovation #BiotechIndustry

Steffen-Sebastian is a scientist, physician, entrepreneur and co-founder and Chief Scientific Officer of Aphaia Pharma AG, a Swiss-based innovative clinical stage biopharma company. Steffen-Sebastian also holds a full professorship at the University of Toronto, Canada, is a Principal Investigator at the Ted Rogers Centre for Heart Research, and Director of the Toronto Centre for Microvascular Medicine. His basic research program has contributed novel signalling paradigms, methodological advancements and validated innovative molecular/therapeutic targets to the field of microvascular medicine.   Steffen-Sebastian is a member of a European biotech investor network and founder and Chief Scientific and Medical Officer at Qanatpharma. He trained at the Universities of Lübeck, Montreal (McGill) and Munich. Meet Steffen-Sebastian Bolz @ #Sachs_BOIF More Info @ https://lnkd.in/dyF_BCWq #ObesityInnovation #BioPharma #ObesityTreatment #HealthcareInnovation #BiotechInvestment #LifeSciences #Cardiometabolic #BiotechInObesity #BioPharmaIndustry #BiotechConference #ObesityEpidemic #TherapeuticInnovation #ObesityHealth #InvestmentOpportunity #BioTechInvestment #InnovationInHealth

Doug Drysdale is the Chief Executive Officer of Cybin Inc. During Doug’s tenure as CEO of Cybin, the company was taken public on the NYSE and now has two development programs in the clinic, with its lead depression program in Phase 3 studies. During Doug’s 30+ years of experience in the healthcare sector, he has built cohesive management teams, recruited board members, created multinational operations, and has raised around $4 billion of both public and private capital. As founding CEO of Alvogen, Doug led the company from inception to around $500mm in revenues, across 35 countries.  Previously, Doug was Head of M&A at Actavis Group, leading 15 corporate acquisitions across three continents between 2004 and 2008. In 2012 Doug was named E&Y Entrepreneur of the Year. Meet Doug Drysdale @ #Sachs_NIF More Info @ https://lnkd.in/dHgcp4fq #Neuroscience #Neurotech #NeurologyInnovation #BrainHealth #CNSDisorders #NeurologicalDiseases #ADPD #Neuropsychiatry #PsychedelicResearch #NeuroTechInvestment #Biotech #MedicalInnovation #NeuroscienceForum #NeuroInvestment #NextGenMedicine #NeuroscienceResearch #MentalHealthInnovation #BiotechIndustry

Harith Rajagopalan, M.D., Ph.D., is Co-founder and CEO of Fractyl Health, having started the company while serving as an Entrepreneur-in-Residence at General Catalyst Partners. Prior to founding Fractyl, Harith was an academic cardiologist and physician-scientist. He received his B.S. in chemistry from Stanford University and went on to obtain M.D. and Ph.D. degrees from Johns Hopkins School of Medicine. At Johns Hopkins, Harith did groundbreaking and award-winning research on intestinal cancers that was published in top medical journals, including Nature and Science. After medical school, Harith trained in internal medicine and clinical cardiology at Brigham and Women’s Hospital and completed a research fellowship at the Harvard Stem Cell Institute at Harvard Medical School. Meet Harith Rajagopalan @ #Sachs_BOIF More Info @ https://lnkd.in/dyF_BCWq #ObesityInnovation #BioPharma #ObesityTreatment #HealthcareInnovation #BiotechInvestment #LifeSciences #Cardiometabolic #BiotechInObesity #BioPharmaIndustry #BiotechConference #ObesityEpidemic #TherapeuticInnovation #ObesityHealth #InvestmentOpportunity #BioTechInvestment #InnovationInHealth

He is a specialist in the Biotech Industry. BSc in Biology and PhD in Biochemistry (Molecular Biology) from the University of Barcelona. Later he was EU post-doctoral fellow in the Faculty of Medicine at the University of Ghent in Belgium and Senior Investigator at the Flemish Institute of Biotechnology (VIB). He completed an Executive education program (PADE) at the IESE Business School in Barcelona and several other additional educational programs in finances. In June 2000, he founded Oryzon Genomics SA together with Dr Tamara Maes, where, since inception, he has served as CEO and Chairman of the Board. He has the Diploma of Professional Board Director from the IC-A of Madrid. He has also been an NED or advisor in other biotechnology companies and Non-Exec Director of the Venture Capital Firm Inveready since January 2009 till 2021 and the Venture Capital Firm Inveredy-Biotech since January 2013 till 2021. He is founder of MENDELION LIFESCIENCES SL. He is currently the First Vice President of the Spanish Association of Biotechnology Companies, ASEBIO, and was the first President of the Catalan Association of Biotechnology Companies, CataloniaBio. He is member of CEAPI (Consejo Empresarial Alianza por Iberoamérica) and a regular stakeholder and collaborator of various key Foundations in the Spanish Science System. Meet Carlos Buesa @ #Sachs_NIF More Info @ https://lnkd.in/dHgcp4fq #Neuroscience #Neurotech #NeurologyInnovation #BrainHealth #CNSDisorders #NeurologicalDiseases #ADPD #Neuropsychiatry #PsychedelicResearch #NeuroTechInvestment #Biotech #MedicalInnovation #NeuroscienceForum #NeuroInvestment #NextGenMedicine #NeuroscienceResearch #MentalHealthInnovation #BiotechIndustry

We are pleased to announce that the 18th Annual European Life Sciences CEO Forum (#Sachs_ELSF) will take place on the 26th - 27th of February 2025 at the Hilton Zurich Airport Hotel. While the European HealthTech CEO Forum will not be held in 2025, the ELSF programme will include some HealthTech topics, such as AI, convergence, and diagnostics. You will also have the opportunity to register for the HealthTech Investment Forum during the Sachs Autumn Life Sciences Week later in the year. The success and longevity of the forum is built on the goodwill and repeat attendance of major corporate and financial investors, and pharma licensing executives and advisors, who are seeking to network with biotechs. The programme and presentations allow all to keep up with the latest industry developments and strategize for 2025. The physical programme will consist of the usual panels and keynotes, which will be available on demand from the 4th of March. Additionally, there will be pre-arranged in-person meetings, live and on-demand company showcases, and a reception. During the online week, virtual meetings will be available through the audio/video online meeting system. Day 1 (Wednesday, 26th of February) Industry Roundtable  Investment Outlook for VC & PE in 2025 Panel  Next-Gen Platforms Panel: Opportunities for Investors New Modalities Panel: The Future of Gene Editing  MedTech, Biotech, & Digital: The Convergence Panel  Advances in the Treatment of Neurological Disorders Panel  Day 2 (Thursday, 27th of February) Pharma Dealmakers Panel  Greater China Biopharma Panel  Partnering in Oncology Panel  Cancer Progress Panel  Early-Stage Investment Panel  Rising Stars – Biotech Seed Companies Session In-Person Meetings – 26th - 27th of February  Virtual Meetings via Online Meeting System – 4th - 6th of March  Networking Reception – 26th of February  On-Demand Content – from 4th of March #LifeSciences #BiotechInEuropeForum #EuropeanBiotech #PharmaIndustry #BiotechConference #HealthTech #GeneEditing #InvestmentForum #VCandPE #Biopharma #PartneringInOncology #CancerResearch #MedTech #BioPharma #DigitalHealth #InvestmentOpportunities #BiotechStartups #OncologyInnovation #BiotechInvestment #LifeSciencesInnovation